Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$26.12 +0.5%	$23.42	$13.40 ▼ $26.65	$4.42B	0.75	2.16 million shs	596,475 shs
CYTK Cytokinetics	$48.28 +36.7%	$36.25	$29.31 ▼ $59.39	$5.77B	0.62	1.77 million shs	5.56 million shs
KRYS Krystal Biotech	$147.02 -0.5%	$146.02	$122.80 ▼ $207.84	$4.26B	0.66	326,660 shs	39,925 shs
SPRY ARS Pharmaceuticals	$11.31 -2.6%	$16.46	$10.00 ▼ $18.90	$1.12B	0.88	1.60 million shs	515,512 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+2.65%	+10.45%	+18.24%	+56.76%
CYTK Cytokinetics	0.00%	-4.54%	-3.71%	+10.41%	-38.10%
KRYS Krystal Biotech	0.00%	+0.63%	-5.91%	+12.83%	-24.30%
SPRY ARS Pharmaceuticals	0.00%	-13.99%	-32.36%	-20.03%	-10.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.7937 of 5 stars	3.3	2.0	0.0	2.5	4.2	2.5
CYTK Cytokinetics	4.0567 of 5 stars	4.5	1.0	4.6	2.8	0.8	0.0
KRYS Krystal Biotech	4.7322 of 5 stars	3.4	1.0	4.7	2.3	3.3	3.1
SPRY ARS Pharmaceuticals	2.8902 of 5 stars	3.6	0.0	0.0	3.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	10.56% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$71.58	48.26% Upside
KRYS Krystal Biotech	2.88	Moderate Buy	$210.38	43.09% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	174.00% Upside

Current Analyst Ratings Breakdown

Latest SPRY, ACAD, KRYS, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	CYTK Cytokinetics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$78.00
9/2/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
8/22/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$219.00 ➝ $216.00
8/22/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/8/2025	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.60	$0.71 per share	36.87	$4.40 per share	5.94
CYTK Cytokinetics	$18.47M	312.81	N/A	N/A	($1.15) per share	-41.99
KRYS Krystal Biotech	$290.52M	14.65	$4.62 per share	31.85	$32.90 per share	4.47
SPRY ARS Pharmaceuticals	$89.15M	12.54	N/A	N/A	$2.64 per share	4.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.68	34.36	6.62	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.10	N/A	N/A	N/A	-707.17%	N/A	-45.52%	11/5/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.92	29.91	14.59	N/A	40.85%	15.21%	13.81%	11/3/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	11/12/2025 (Estimated)

Latest SPRY, ACAD, KRYS, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/7/2025	Q2 2025	CYTK Cytokinetics	-$1.34	-$1.12	+$0.22	-$1.12	$1.95 million	$66.77 million
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.08	$1.29	+$0.21	$1.29	$95.42 million	$96.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
CYTK Cytokinetics	N/A	6.76	6.76
KRYS Krystal Biotech	N/A	9.68	9.33
SPRY ARS Pharmaceuticals	0.37	6.17	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CYTK Cytokinetics	N/A
KRYS Krystal Biotech	86.29%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
CYTK Cytokinetics	3.40%
KRYS Krystal Biotech	13.70%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	120.97 million	Optionable
CYTK Cytokinetics	250	119.66 million	115.59 million	Optionable
KRYS Krystal Biotech	210	28.94 million	24.98 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable

SPRY, ACAD, KRYS, and CYTK Headlines

Recent News About These Companies

Wellington Management Group LLP Sells 31,476 Shares of ARS Pharmaceuticals, Inc. $SPRY

September 2 at 4:11 AM | marketbeat.com

Raymond James Financial Inc. Purchases 83,506 Shares of ARS Pharmaceuticals, Inc. $SPRY

September 2 at 3:50 AM | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus Target Price from Analysts

September 2 at 2:23 AM | americanbankingnews.com

Kodai Capital Management LP Acquires New Position in ARS Pharmaceuticals, Inc. $SPRY

September 1 at 5:52 AM | marketbeat.com

Nuveen LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY

September 1 at 3:34 AM | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Buy" by Brokerages

September 1 at 2:43 AM | marketbeat.com

Epoch Investment Partners Inc. Takes Position in ARS Pharmaceuticals, Inc. $SPRY

August 30 at 5:28 AM | marketbeat.com

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

August 28, 2025 | globenewswire.com

Vanguard Group Inc. Has $43.88 Million Holdings in ARS Pharmaceuticals, Inc. $SPRY

August 28, 2025 | marketbeat.com

ARS Pharmaceuticals Inc. (SPRY) Stock Price Today - WSJ

August 24, 2025 | wsj.com

ARS Pharmaceuticals (NASDAQ:SPRY) CFO Sells 12,500 Shares

August 23, 2025 | insidertrades.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 2.3% Following Insider Selling

August 23, 2025 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells $173,186.32 in Stock

August 22, 2025 | insidertrades.com

Aberdeen Group plc Takes $12.61 Million Position in ARS Pharmaceuticals, Inc. $SPRY

August 21, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

August 19, 2025 | marketbeat.com

Leerink Partnrs Issues Negative Forecast for SPRY Earnings

August 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for SPRY Q3 Earnings

August 19, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

August 15, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

ARS Pharma Sales Jump 3,040% in Q2

August 14, 2025 | aol.comA

ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For

August 14, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, ACAD, KRYS, and CYTK Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$26.12 +0.13 (+0.49%)

As of 10:57 AM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Cytokinetics NASDAQ:CYTK

$48.28 +12.95 (+36.66%)

As of 10:57 AM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$147.02 -0.68 (-0.46%)

As of 10:57 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

ARS Pharmaceuticals NASDAQ:SPRY

$11.31 -0.31 (-2.63%)

As of 10:57 AM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time